Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-REGN3504 PET Imaging in Advanced PD-L1 Positive Malignancies
NCT03746704Phase 1Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 89Zr-DFO-REGN3504 in malignant neoplasm, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 90 days. Started Sep 2019; status: terminated.
02
Drugs
89Zr-DFO-REGN3504
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT03746704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746704.